Navigation Links
Schering-Plough Schedules Conference Call Webcast for 2009 Second Quarter Earnings
Date:6/29/2009

KENILWORTH, N.J., June 29 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) is scheduled to announce its sales and earnings results for the 2009 second quarter on Tuesday, July 21, 2009.

At approximately 7:45 a.m. (EDT) on that day, Schering-Plough will conduct a conference call to review results for the 2009 second quarter. Fred Hassan, Schering-Plough's chairman and CEO, and other members of management will host the conference call.

To listen live to the call, dial 1-866-871-2144 or 1-706-634-5003 and enter conference ID # 13268740. A replay of the call will be available beginning later on July 21 through 5 p.m. on Tuesday, July 28. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID # 13268740. A live audio webcast of the conference call also will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available starting on July 21 through 5 p.m. on August 21.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
2. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
3. Schering-Plough Schedules Webcast For Annual Meeting of Shareholders
4. Schering-Plough Schedules Conference Call Webcast for 2009 First Quarter Earnings
5. Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
6. Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France
7. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
8. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
9. Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
10. Schering-Plough to Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
11. HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... survive impact by the huge amounts of energy ... energy for photosynthesis. The hypothesis is that the ... the energy throughout the entire protein molecule through ... now managed to successfully ,film, this process. , ... which play a role in photosynthesis and thus ...
(Date:8/27/2014)... ANGELES , Aug. 27, 2014  Lisa Kulik ... years this July 4 holiday, thanks to a groundbreaking ... Ph.D., an internationally renowned clinician-researcher at the University of ... a 55-year-old Peoria, Ariz. resident ... robs its victims of sight. On June 2, she ...
(Date:8/27/2014)... -- Reportbuyer.com has added a new market research ... Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... similar amount of hype currently surrounds graphene, with ... water treatment, but is graphene the only solution? ... Opportunity Report, authored by Tim Harper ...
(Date:8/27/2014)... -- ARCH Venture Partners, one of the largest U.S. ... seed and early-stage advanced technology companies, today announced ... than $400 million in subscriptions. ARCH Venture Fund ... more than $150 million. "The enthusiasm ... of our approach to finding and funding new ...
Breaking Biology Technology:DTU researchers film protein quake for the first time 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... been proposed for regenerative medicine and tissue replacement after ... to efficiently develop into the desired specific cell type ... neurons now limits the potential clinical utility of ... within aggregates of embryonic stem cells via biodegradable microspheres ...
... Ill., April 9 Baxter Healthcare Corporation,today ... VitalShield,protective coating, the first needleless intravenous (IV) ... available for hospitals in the,United States and ... to kill on,average 99.9 percent or more ...
... April 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... its U.K. combination REOLYSIN(R) and carboplatin/paclitaxel,trial. Dr. ... Research, London,and the principal investigator for the ... Annual Conference of the British Society for ...
Cached Biology Technology:Method to deliver molecules within embryonic stem cells improves differentiation 2Method to deliver molecules within embryonic stem cells improves differentiation 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 2Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 4Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial 3
(Date:8/27/2014)... listen carefully to someone, the first thing we do ... stop moving altogether. This strategy helps us hear better ... , This interplay between movement and hearing also has ... has long suggested that the brain,s motor cortex, which ... rise to our conscious perception of sound. , A ...
(Date:8/27/2014)... often depicted as giant, frightening beasts. But every creature ... a rock slab containing fossils of 24 very young ... group of hatchlings overseen by a caretaker, according to ... Penn,s Brandon P. Hedrick and Peter Dodson led the ... Natural History, where the specimen is held. Hedrick is ...
(Date:8/27/2014)... the long-standing belief that a deficiency in serotonin ... central role in depression. In the journal ACS ... ability to make serotonin in their brains (and thus ... show depression-like symptoms. , Donald Kuhn and colleagues ... Wayne State University School of Medicine note that depression ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3New study throws into question long-held belief about depression 2
... National Institutes of Health (NIH) announced today a new ... articles resulting from NIH-funded research. The policy ?the first ... release to the public manuscripts from research supported by ... of final publication. , These peer-reviewed, NIH-funded research publications ...
... Medical School, demonstrating how malaria parasites form mutations that ... the key to a new treatments for a disease ... , The scientists developed disease models using yeast and ... the anti-malarial drug, atovaquone. The study, featured as the ...
... for humans and most animals but not Australia's green-striped ... University of Queensland has found that unlike most animals, ... the green-striped burrowing frog is able to absorb nutrients ... than frogs that had eaten regularly. , "They can ...
Cached Biology News:NIH Calls on Scientists to Speed Public Release of Research Publications 2NIH Calls on Scientists to Speed Public Release of Research Publications 3Molecular models advance the fight against malaria 2A frog's life is food for thought 2A frog's life is food for thought 3
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [Flt-1/EWC] to VEGF Receptor 1 ( Abpromise for all tested applications). entrezGeneID: 2321 SwissProtID: P17948...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: